[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-434196-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-434196-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","solidification-of-snedds-using-mesoporous-carriers-20202025-a-review-of-design-biopharmaceutical-enhancement-and-therapeutic-impact","Solidification of SNEDDS Using Mesoporous Carriers (2020–2025) - A Review of Design, Biopharmaceutical Enhancement, and Therapeutic Impact","","Self-nanoemulsifying drug delivery systems (SNEDDS) are developed to enhance bioavailability of poorly water-soluble drugs via nanoscale emulsification. Liquid SNEDDS often face stability and handling limitations, so solidification is used to produce solid SNEDDS (S-SNEDDS) by incorporating solid carriers. This review evaluates mesoporous-based S-SNEDDS, emphasizing formulation design, solidification strategies, and biopharmaceutical outcomes from 2020–2025 literature. Mesoporous magnesium alumino-metasilicate and mesoporous silica are mainly reported with physical adsorption, improving physical stability and translating into better dissolution, permeation, and pharmacokinetic/pharmacodynamic performance. Future work should address regulatory aspects, deepen mechanisms, and compare carriers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/solidification-of-snedds-using-mesoporous-carriers-20202025-a-review-of-design-biopharmaceutical-enhancement-and-therapeutic-impact/434196/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/solidification-of-snedds-using-mesoporous-carriers-20202025-a-review-of-design-biopharmaceutical-enhancement-and-therapeutic-impact/434196.png","ImageObject",300,407,{"name":42,"@type":43},"Jake","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is SNEDDS solidification used instead of relying only on liquid SNEDDS?","Question",{"text":63,"@type":64},"Solidification converts liquid SNEDDS into solid SNEDDS to improve practicality and robustness, enabling further processing into tablets, capsules, or pellets while reducing handling issues and storage-related precipitation risks.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role do mesoporous carriers play in solid SNEDDS?",{"text":68,"@type":64},"Mesoporous materials provide high surface area, tunable pore sizes, and strong adsorption capacity, supporting efficient drug incorporation and contributing to improved physical stability.",{"name":70,"@type":61,"acceptedAnswer":71},"How do mesoporous-carrier S-SNEDDS affect drug performance in vitro and in vivo?",{"text":72,"@type":64},"The review reports improved dissolution and permeation, which typically translates into superior pharmacokinetic and pharmacodynamic outcomes compared with less effective solidification approaches.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},434196,1790822130,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},962084928904,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Drug Design, Development and Therapy  \nOpen Access Full Text Article REVIEW  \nSolidification of SNEDDS Using Mesoporous Carriers (2020–2025): A Review of Design, Biopharmaceutical Enhancement, and Therapeutic Impact  \nSani Ega Priani 1 , 2 , *, Adilah Nurhaliza 2 , *, Anis Yohana Chaerunisaa 3 , *, Gofarana Wilar4 , *, Iyan Sopyan 3 , *  \n1Doctoral Program of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia; 2Department of Pharmacy, Bandung Islamic University, Bandung, Indonesia; 3Department of Pharmaceutics and Technology of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia; 4Department of Pharmacology and Clinical Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia  \n*These authors contributed equally to this work  \nCorrespondence: Iyan Sopyan, Department of Pharmaceutics and Technology of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia, Tel +6222 84288888, Email [i.sopyan@unpad.ac.id](i.sopyan@unpad.ac.id)  \n\n| Abstract: Self-nanoemulsifying drug delivery systems (SNEDDS) have been widely developed as a practical approach to enhance the bioavailability of poorly water-soluble drugs through nanoscale emulsification. To improve the stability and practicality of liquid systems, solidification is commonly performed to obtain solid SNEDDS (S-SNEDDS) by incorporating appropriate solid carriers. Among various options, mesoporous materials have attracted significant attention due to their high surface area, tunable pore sizes, and excellent adsorption capacity. This review aims to summarize and critically analyze recent advances in mesoporous-based S-SNEDDS, focusing on formulation design, solidification strategies, and associated biopharmaceutical outcomes. The review is based on research articles published between 2020 and 2025 retrieved from reputable scientific databases (PubMed, ScienceDirect, Taylor & Francis, Springer, Scopus, and Web of Science) and selected for their relevance to mesoporous carriers and S-SNEDDS development. Findings reveal that carriers such as mesoporous magnesium alumino-metasilicate (eg, Neusilin® ) and mesoporous silica (eg, Syloid® ) have primarily been reported in studies employing physical adsorption. These systems generally exhibit favorable micromeritic properties and solid-state characteristics, suggesting successful drug incorporation within the carrier matrix and improved physical stability. These systems consistently demonstrate enhanced dissolution and permeation, and subsequently translate into superior pharmacokinetic and pharmacodynamic performances. Overall, the solidification of SNEDDS using mesoporous carriers successfully yields systems with desirable physical properties and improved in vitro and in vivo performances. Future research should address regulatory considerations for mesoporous excipients, deepen mechanistic insights into drug–carrier interactions, and include comparative evaluations among different carriers to support clinical and industrial advancement.\u003Cbr>Keywords: S-SNEDDS, mesoporous carriers, solubility enhancement, adsorption method, bioavailability |\n| --- |\n| Introduction\u003Cbr>Poor aqueous solubility remains a significant barrier to the oral delivery of Biopharmaceutics Classification System (BCS) Class II and IV drugs, often resulting in suboptimal dissolution, limited absorption, and inadequate therapeutic performance.1 Lipid-based formulations offer an attractive means to address these limitations, with self-nanoemulsifying drug delivery systems (SNEDDS) emerging as one of the most effective approaches to improve the solubility and bioavailability of poorly water-soluble drugs.2,3 SNEDDS are composed of oil, surfactant, and cosurfactant, and are therefore referred to as nanoemulsion preconcentrates.4 In the Lipid Formulation Classification System (LFCS), most SNEDDS are categorized as Type III formulations, which contain oils and relatively high levels of surfactants that |\n\nReceived: 27 October 2025  \nAccepted: 18 December 2025  \nPublished: 3","cbCaioa87KIQCXS0","https://ap.wps.com/l/cbCaioa87KIQCXS0","pdf",1884196,29,"English","# Abstract\n# Introduction\n# Solidification of SNEDDS Using Mesoporous Carriers (2020–2025)\n## Formulation design\n## Solidification strategies\n## Biopharmaceutical outcomes\n# Conclusion and Future Perspectives","[{\"question\":\"Why is SNEDDS solidification used instead of relying only on liquid SNEDDS?\",\"answer\":\"Solidification converts liquid SNEDDS into solid SNEDDS to improve practicality and robustness, enabling further processing into tablets, capsules, or pellets while reducing handling issues and storage-related precipitation risks.\"},{\"question\":\"What role do mesoporous carriers play in solid SNEDDS?\",\"answer\":\"Mesoporous materials provide high surface area, tunable pore sizes, and strong adsorption capacity, supporting efficient drug incorporation and contributing to improved physical stability.\"},{\"question\":\"How do mesoporous-carrier S-SNEDDS affect drug performance in vitro and in vivo?\",\"answer\":\"The review reports improved dissolution and permeation, which typically translates into superior pharmacokinetic and pharmacodynamic outcomes compared with less effective solidification approaches.\"}]","Solidification of SNEDDS Using Mesoporous Carriers (2020–2025) - A Review of Design, Biopharmaceutical Enhancement, and Therapeutic Impact | PDF",1790667626,73]